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Abstract 
Octodon degus (O. degus) is a diurnal rodent that spontaneously develops several 
physiopathological conditions, analogous in many cases to those experienced by humans. In light 
of this, O. degus has recently been identified as a very valuable animal model for research in 
several medical fields, especially those concerned with neurodegenerative diseases in which risk 
is associated with ageing. O. degus spontaneously develops β-amyloid deposits analogous to 
those observed in some cases of Alzheimer’s disease (AD). Moreover, these deposits are 
thought to be the key feature for AD diagnosis, and one of the suggested causes of cell loss and 
cognitive deficit. This review aims to bring together information to support O. degus as a valuable 
model for the study of cerebral aging. 
 
Keywords: Memory, Mild Cognitive Impairment, Alzheimer disease, Octodon degus, Amyloid 
beta-protein 
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Introduction 
One of the major areas of interest in the field of neuroscience is the study of age-related brain 
pathologies. Understanding the origin of such pathologies, as well as how they progress through 
different cellular mechanisms and how this process finally affects cognitive and behavioral 
processes is essential for developing therapies and intervention strategies. Among the vast 
variety of brain pathologies, Alzheimer’s disease (AD) deserves special attention. Being a 
neurodegenerative disease, the symptoms do not appear spontaneously, but, unlike in the case 
of a psychosis or amnesia, gradually. The pathology progresses relentlessly until the symptoms 
are manifest and the memory function, as well as other cognitive domains such as orientation, 
problem solving or even changes in personality, become apparent. In most cases, patients are no 
longer able to take care of themselves and require full-time care 1. 
 
Basic research in Alzheimer’s disease 
There are currently no approved disease-modifying treatments that are able to halt of slow down 
the pathology in AD or other common neurodegenerative disease. There are, however, vast 
ranges of different pharmacological and psychological therapies in development stages that aim 
to slow down the advance of functional loss. However, it is clear that we need to understand 
more about the cause of this disease and its natural progression if we are to understand when 
and how to treat it. 
There are several approaches to the study of AD, including those based on cellular models 2-4. 
Nonetheless, although these models may be very useful for unraveling the molecular 
mechanisms that underlie the symptomatology, there is a great gap between the conclusions 
deduced from them and the clinical outcome that this disease displays. On the other hand, the 
use of animal species may contribute not only to understanding cellular and pathophysiological 
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characteristics of Alzheimer’s, but also to reproduce the cognitive deficits shown in patients. In 
our mind, this could seem a more ecological and appropriate approach and one more suited for a 
better appreciation of the different features of the illness. In this sense, we could say that animal 
models are good for their capacity to imitate both pathophysiological conditions and behavioral 
outcome (if any). Therefore, it is fundamental for such models to be able to measure cognitive 
and behavioral function in an accurately and reliably way.  
A number of animal models have been generated in an attempt to reproduce AD pathology.  Most 
of these models have used rodents and there have been some promising advances 5-7. Several 
studies have demonstrated that Alzheimer pathology markers are absent in wild-type rodents, 
making it necessary to generate transgenic animals overexpressing human amyloid precursor 
protein (β-APP) harboring familial AD mutations 8-10 or to perform intracerebral injections of Aβ 
aggregates 11,12 to achieve homologous states of the disease. 
Despite the wide range of animal models that are currently used in the study of behavioral and 
physiopathology features of AD 13, rodents are the most utilized. In the last decades, for instance, 
the number of transgenic models that have been developed has remarkably increased, widening 
the alternatives and targeting those characteristics that most significantly are identified within this 
neurodegenerative disease 14. As the Aβ cascade is the main hypothesis for the AD, the 
achievement of models that lead to the development of such characteristics is a milestone for the 
advance in understanding this pathology.  
In this sense, following the Aβ hypothesis, transgenic models are mainly derived from different 
branches that over express three hallmarks identified as regard the AD: APP protein, presenilin 1 
and 2, and tau protein 15, aiming to develop the characteristic amyloid accumulation and 
neurofibrillary tangles (NFTs) 16. The major advantage of these models is that they succeed in 
reproducing a similar pathophysiological and behavioral outcome that is observed among AD 
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patients 17,18. However, although transgenic models have proved their value for the study of AD, 
they raise important restrictions.  
In the first place, to our view, the most important limitation these models present is the need for 
genetic and/or pharmacological manipulation to reach the inherent pathophysiological state of 
Alzheimer’s. For instance, it is known that AD patients show a significant neuron loss 19, and this 
feature has to be implanted in the mouse because even transgenic models show no such loss 
without manipulation 20. Another important similarity between human and rodent pathology that 
these models lack of, is the anatomical distribution of the senile plaques and NFT accumulation 
17. In humans, neuronal death derived from these two properties has been primarily located in the 
prefrontal and parietal cortices (mainly hippocampus) 16. However, this allocation has not been 
achieved with the different models available. Taking this into account, the availability of a model 
that may cover these limitations would be undoubtedly appreciated. 
In recent years, a rodent endogenous to Chile, the Octodon degus (O. degus) has gained 
prominence as a valued model for many different diseases, including those related with 
neurodegeneration, since this animal may develop naturally several symptoms that can be linked 
to a similar number of pathological conditions (Figure 1). Because of its particular diurnal cycle, it 
has frequently been used in circadian studies 21,22. It is also a highly social rodent, which explains 
its role in social and neuroaffective research 23,24. However, over the last few years, the 
participation of degus in the study of neurodegeneration has suggested that this area of research 
is the most promising application of this model. This diurnal cavimorph rodent lives up to 7 years 
average in captivity 25, making it per se an interesting model for use in longitudinal studies, 
including those related in the neuropsychobiology of ageing, and AD.  
 
Octodon-Human Aβ  aggregates similarities 
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Among the different hypotheses raised to explain the origin and evolution of AD, the most widely 
held is that which stresses the importance of cholinergic neurodegeneration and the appearance 
of two principal markers: the NFTs formed through the dysfunctional hyperphosphorylation of tau 
protein, and the deposition of Aβ aggregates, which are thought to be the trigger for neuronal 
death 26. However, the relationship between these two elements is not clear, although several 
hypotheses have attempted to link them 26,27. 
A few years ago, Inestrosa and collaborators demonstrated that O. degus naturally develop 
characteristic histopathological hallmarks typical to those found in AD patients 28. The discovery 
showed that this rodent, in its natural environment, might produce plaques in different brain areas 
29, including hippocampus and frontal cortex, both of which are severely affected in AD patients 
16. Moreover, immunohistochemical and genetic analyses performed on the O. degus revealed a 
high degree of similarity between human deposits and the Aβ precursor protein (Aβ-PP). Also, 
RT-PCR analysis showed the O. degus and human Aβ peptide sequence to be 97.5% 
homologous 28. This animal presents only one amino acid substitution with respect the human, 
which presents an advantage to other models (rats, for example, present in their Aβ sequence 
three amino acid substitution) (Figure 2). In this sense, differently to transgenic animals, there is 
no need to overexpress this human APP to generate significant levels of amyloid protein, which 
will help to avoid the overexpression of APP. This is an important question, since it has been 
postulated as to why there is a limited neuronal loss in the APP transgenic models, and is one of 
the main advantages of the O. degus as a model in preclinical research in AD. 
Nevertheless, as promising as this animal might be, it still needs to satisfy certain requirements 
before it can be used as an appropriate model. In this sense, it is worth mentioning that the 
histopathological changes occurring in O. degus brains are only observed in aged animals 28,29, 
and have never been detected in young animals so far. Similar comments may be made 
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regarding tau, which suggests that amyloid and tau deposition are age-dependent, as they are in 
AD patients 30,31 and in some of the more successful transgenic mice studied to date 10. 
Another interesting analogy concerns the cholinergic system. The cerebral cortex of some human 
and non-human primates contains acetylcholine (AChE)-rich pyramidal neurons, which have 
been seen to decline in numbers during the progression of AD, a decrease claimed to be partly 
responsible for the memory deficits in Alzheimer patients 15,19. O. degus apparently shares the 
same AChE-rich neurons that are found in the cerebral cortex of adult humans. Moreover, the 
high degree of homology (97.5%) between the human and O. degus in Aβ sequence and the Tau 
structure, possibly triggered by the Aβ found in these animals, suggest that both play a major role 
in the appearance of AD markers in this rodent, including the presence of extra- and intracellular 
amyloid deposits and NFTs 10,28,31. 
 
Octodon degus, what does it offer?  
We have already mentioned the histological advantages that this model presents for AD 
research. However, without a cognitive counterpart, assessment of this model is not complete. As 
mentioned above, one of the key features of an animal model for AD should be its ability to mimic 
the cognitive and behavioral response in the different domains affected by this illness. 
It has been recently demonstrated that the age-progressive accumulation of Aβ oligomers and 
phosphorylated tau proteins in O. degus from 12 to 36 months, negatively correlated with their 
performance in spatial and object recognition memory measured by two different behavioral 
paradigms: the Object Recognition Memory task and a spatial T-Maze. In this work, Ardiles et al. 
demonstrate that memory performance declines in an age-dependent manner, as aged animals 
committed less correct choices in the arms of the T-Maze and the time spent exploring the novel 
objects was significantly reduced in the object recognition task. Interestingly, the synaptic 
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strength in the old O. degus was reduced compared with the young ones, and the postsynaptic 
transmission was also impaired 32. 
As memory impairment is the first manifestation of AD symptoms and the most prominent of 
observable consequences, one of the requirements that O. degus should fulfill is that it should 
discriminate in different cognitive tests different memory deficits classically impaired in AD. 
Moreover, this should be achieved in response to the different challenges that are used to induce 
cognitive impairment, one of the most widespread of which is sleep deprivation.  
Sleep deprivation (SD) has been widely documented as one of the challenges that most 
effectively induce transient cognitive impairment 33-36 in animals 37-39 and humans 40. SD has also 
been studied in the O. degus 41 (Figure 3). This condition affects the formation, expression and 
retrieval of memories 35,36, and produces a deficient consolidation in both procedural and 
declarative memories 33,42. Evaluating memory impairment caused by this challenge in the O. 
degus is especially interesting, given their phase inversion capacity 22. Sleep-wake deregulation 
is commonly seen in AD  43,44, and is displayed as agitation, disrupted sleep or breathing 
difficulties 43. Sleep studies performed on O. degus have demonstrated that, despite being 
diurnal, this animal is able to switch from diurnal to nocturnal phase behavior in a few days 45. 
Together with all the AD-like hallmarks displayed by this rodent, this chronobiological 
characteristic adds value to the O. degus as an attractive model of the cognitive decline and 
behavioral outcome observed in age-related neurodegenerative diseases, and also confirms SD 
as an appropriate methodological choice. With this method, researchers would be able to induce 
transitory memory deficits in both young and old animals to further compare the impact of such 
procedure and the effect of aging and histopathological hallmarks formation on the behavioral 
outcome. 
The most noteworthy feature of AD is memory loss, but it is not the only one. Besides the well-
known deficit in problem solving 46,47 and spatial orientation 47,48, patients with Alzheimer’s also 
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present a wide range of psychological affectations such as stress 49 and anxiety 50,51, as well as 
different systemic impairments 52. In this sense, it has been demonstrated that the O. degus may 
develop atherosclerosis, a pathological states frequently concomitant with AD 53. It has been 
demonstrated that this rodent is able to develop an atherosclerosis condition directly derived from 
a rich-cholesterol diet, together with a lipoprotein metabolism similar to humans, being 54. This, 
combined with the presence of hyperglycemia strongly correlates with the appearence of a type-2 
diabetes 55. Interesntingly, aged O. degus also share with humans these pathological conditions 
54. 
Despite the fact that many studies have shared inconsistent results concerning age-related 
changes in anxiety in different rodent models 56,57, there is evidence of a significant age-related 
effect in O. degus (young and old adults) in the open field test and dark-and-light test, two widely 
validated procedures to assess anxiety in rodent models 58. Popovic and collaborators explored 
the relationship between age and anxiety and demonstrated that, the older group spent less time 
in the center of the open field, compared with the young adult group 59, and that the latter group 
were more willing to spend more time in the light than the older ones 59, suggesting that anxiety 
may increase with age in these animals. 
Another AD-like symptom that is apparent in the O. degus is related to their social life. It is known 
that in many cases of AD, patients tend to develop social problems mainly for two reasons: 
because of the dementia associated with the disorder 60 and the stress causes to caregivers 
61,62. O. degus is generally described as a very social rodent with a highly complex social 
behavior 23,24. However, as in AD, this animal is also subjected to problematic interactions with 
other members of its colony when stressful events occur 63. In this sense, Poeggel and 
colleagues reported severe behavioral deficits and neural alterations in the frontal cortex 64, which 
has also shown to be affected in AD patients 62,65. 
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It is also common to find patients that have difficulty in manipulating complex objects, or 
performing fine motor movements 66,67. To date, the range of possibilities to test this particular 
deficit is scarce, and is mainly confined to non-human primates. However, to the best of our 
knowledge there is no literature covering manipulative and fine motor problems in rodents. Thus, 
it is worth mentioning that O. degus is the only rodent to date which has been demonstrated to be 
sensitive to training in object manipulation towards obtaining a reward 68. The authors of this work 
were able to train 5 animals to retrieve a food reward located in a platform that could only be 
reached using one of the different tools to which they were given access. Animals learned the 
task with the same efficiency as shown by non-human primates in similar conditions 69, 
demonstrating an increasingly understanding of tool usage, not only regarding the physical 
properties of the tool, but also its functional attributes 68. 
 
Further directions 
We have reviewed a range of studies performed with the O. degus, a diurnal rodent native to 
Chile. The main interest in this animal in the field of cognition is that it has recently been 
proposed as a putative model for AD, principally because it presents two of the major 
histopathological markers for this disorder (β-Amyloid plaques and neurofibrillary tangles 
containing hyperphosphorylated tau). Several reports have also suggested that cognitive 
impairment in O. degus may be compared with that observed in humans. Therefore, this animal 
could represent one of the most promising models for the study of cognitive impairment 
associated with AD impairment. Whilst investigation with O. degus in the field of cognitive 
sciences is still in its early stages, we believe that the degus provides an excellent opportunity for 
exploring the mechanisms underlying late developmental changes in the nervous system, and 
therefore, the behavioral and cognitive outcomes resulting from such changes. 
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Figure 1. Characteristics of O. degus. Brief description of several characteristics that naturally 
develop in the O. degus making it useful as an animal model in several fields. Numbers in 
brackets are for the correspondent reference in the bibliography. 
 
Figure 2. Amino acid Aβ  sequence. Differences and similarities between mice/rat, human and 
O. degus amino acid Aβ sequence. Differently from the mice/rat, the O. degus is only one amino 
acid different from the human sequence 28,29. 
 
Figure 3. Procedural scheme of the sleep deprivation induced by gentle handling. Adapted 
to the normal diurnal activity of the O. degus, sleep deprivation challenge starts at 7 p.m. in a 
12/12-hour light and dark cycle. Gentle handling is a non-stressful way of preventing the animal 
from sleeping. After the procedure, the behavioral test takes place 41. 
	   21	  
 
 
 
